DE | Accessible presentation
Translations are powered by AI

How Munich biotech startups are fighting cancer

Munich is one of Germany's leading biotech hubs. Research is being conducted here on a wide variety of drugs and therapies, including cancer treatments. We'll introduce you to five startups in more detail.

February 21, 2023 4 min reading time

Catalym
In immunotherapies, the body's own immune system is directed against the cancer. This treatment method is considered a particularly pioneering approach. A major challenge is to combine a highly effective immune response against cancer cells with minimal side effects. The Munich-based startup Catalym is developing new active ingredients for this purpose. The focus is on the drug candidate Visugromab. This is designed to neutralize a specific protein that tumors use to protect themselves from the body's own immune system. This should make the cancer cells accessible to the immune system again, thus strengthening the immune system. With this idea, which stems from research at the University of Würzburg, the startup has already won over numerous investors. Most recently, Catalym closed its €50 million Series C in November of last year. The Munich-based company's total financing is now around €100 million. (Image: kjpargeter / Freepik)
read more ↓